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Background: Lymphatic metastasis is the most important parameter in the spread of gastric carcinomas. Nitric
oxide (NO) is a signaling molecule that plays an important role in inflammation and carcinogenesis. In this study,
the possible link between inducible nitric oxide synthase (iNOS) expression with lymphangiogenesis and the
clinicopathological parameters of gastric carcinomas was investigated.
Methods: In this study, iNOS expression and D2-40 (lymphatic endothelium-specific marker monoclonal antibody)
reactivity were examined immunohistochemically in 41 gastric adenocarcinoma and 20 non-neoplastic gastric
tissues. iNOS expression was scored semiquantitatively in the tumor parenchyma and stroma. D2-40-positive
lymphatic vessels were used in the determination of lymphatic invasion and intratumoral and peritumoral
lymphatic vascular density.
Results: iNOS expression was higher in gastric carcinoma tissue compared with non-neoplastic tissue. Particularly,
iNOS expression in tumor cells was found to be closely related to lymphangiogenesis and lymphatic metastasis. The
density of lymphatic invasion as well as intratumoral and peritumoral lymphatic vascular density were positively
correlated with lymph node metastasis.
Conclusions: Our results suggest that iNOS-mediated NO formation plays an important role in gastric
carcinogenesis, tumor lymphangiogenesis, and the development of lymphatic metastases. Inhibition of the NO
pathway may be an alternative treatment of gastric carcinomas.
Virtual slides: The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1713572940104388.
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Solid tumor growth depends on the proliferative activity
of the tumor as well as tumor angiogenesis [1]. The
most important factors in the initiation and progression
of angiogenesis are nitric oxide (NO) and the vascular
endothelial growth factor (VEGF) family. NO exists in
various cell types and is synthesized from L-arginine by
the nitric oxide synthase (NOS) enzyme family. Indu-
cible nitric oxide synthase (iNOS) is the most-active
NOS isoform [2-4].* Correspondence: niluferkandemir@yahoo.com
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reproduction in any medium, provided the orIn recent years, studies have shown that NO plays an
important role in tumor lymphangiogenesis and lympha-
tic metastasis. NO, which is synthesized by lymphatic
endothelial cells (LECs), regulates lymphatic permeabil-
ity and lymphatic flow. Increased vascular permeability
and vasodilatation by NO facilitates the spread of tumor
cells via lymphovascular invasion (LVI). Additionally,
NO is thought to accelerate lymphangiogenesis via in-
creasing the expression of VEGF-C/VEGF-D and VEGF-
R2/VEGF-R3 [5-7]. Studies of head and neck squamous
cell carcinoma have shown that the NOS activity of
tumor cells is closely associated with lymphangiogenesis
and lymph node metastasis [8].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://www.diagnosticpathology.org/content/8/1/151As with other solid tumors, lymphatic invasion (LI)
and lymph node metastasis are among the most impor-
tant steps of gastric carcinoma progression. However, in
the literature, few studies have investigated the effect of
NOS expression on lymphangiogenesis and lymphatic
metastasis in gastric cancer [5,9-11]. In this study, the
effect of iNOS expression on tumor lymphangiogenesis
was investigated in gastric adenocarcinoma. In addition,
we examined the relationship between iNOS expression
and other clinicopathological prognostic parameters,




41 patients with gastric adenocarcinoma who consecu-
tively underwent surgical resection between 01. 01. 2007
and 30. 12. 2010 were investigated in this study. Clinical
parameters were obtained by review of surgical pa-
thology reports, and the Oncology Data Bank. Patients
undergoing neoadjuvant chemotherapy and/or radio-
therapy were excluded. Surgical margins were confirmed
negative for all cases included in this study. They had no
detectable metastasis in liver, peritoneum, and distant
organ at the time of surgery. No other previous or con-
comitant primary cancer was present. The total number
of dissected lymph nodes of the 41 gastric carcinoma
patients was 1021, with an average of 18.8 ±11.3 (range
15–78) dissected nodes per case. Seventeen (41.5%) of
the cases displayed weight loss, 18 (43.9%) of the cases
diplayed other gastrointestinal symptoms (e.g. stomach-
ache, vomiting, indigestion) and 6 (14.6%) presented
anemia with hemoglobin (HGB) < 90 g/l. 53.7% (n = 22)
of the tumors were in antrum, 14.6% (n = 6) of these in
corpus, and 31.7% (n = 13) of these in cardia. The me-
dian follow-up time of the patients was 16 month and
ranged from 11 to 65 month.
Investigation of gastric carcinoma cases with respect
to conditions accompanying the tumor revealed that 21
(51.2%) patients had Helicobacter Pylori-associated
gastritis, 9 (22%) had intestinal metaplasia, 5 (12.2%) had
chronic atrophic gastritis, 4 (9.7%) had intraepithelial
neoplasia (dysplasia), and 2 (4.9%) had non-neoplastic
polyps. None of the cases had a family history of
“Hereditary diffuse gastric cancer” or a genetically pro-
ven mutation.
Non-neoplastic gastric tissue
This study included non-neoplastic gastric tissues of 20
patients who underwent sleeve gastrectomy for obesity
(9 men, 11 women, ranging in age from 25 to 42 years,
mean 32 ± 9.2 years).
The study was performed in accordance with the
Helsinki Declaration, internationally recognized guidelines,and the privacy of patients was protected by decoding of
data, according to the privacy regulations of the Dr. Lutfi
Kirdar Training and Research Hospital (Istanbul, Turkey).
Written informed consent was obtained from the patient
and the protocol was approved by the Institutional Review
Board.
The study was performed in accordance with the
Helsinki Declaration, and the privacy of patients was
protected by decoding of data, according to the privacy
regulations of the Dr. Lutfi Kirdar Training and Research
Hospital (İstanbul, Turkey).
Pathological evaluation
Gross types of tumors was carried out according to
Borrmann classification. The histopathological diagno-
ses, histological grading, tumour stage, histological type,
Lauren classification, LVI, and local inflammatory
response were confirmed through the examination of
archived hematoxylin and eosin (H&E) slices. Tumor-
node-metastasis (TNM) staging was carried out accor-
ding to the American Joint Committee on Cancer
(AJCC) classification [12,13], and histological grading
was performed according to World Health Organisation
(WHO) criteria [14]. Only patients with histologically
typed adenocarcinoma [not otherwise specified (NOS),
papillary, tubular, mucinous, poorly cohesive carcinoma
(including signet ring cell carcinoma and other variants)]
tumors were included in the sample [14,15]. LVI and LI
in the tumor tissue were evaluated according to previ-
ously defined criteria [16].
Local inflammatory response in the tumor tissue was
evaluated according to the criteria defined by Klintrup
et al. [17]. Tumours were scored based on the appear-
ance at the deepest area of tumour invasion on a four-
point score. A score of 0 indicated that there was no
increase in the inflammatory cells at the deepest point of
the tumours invasive margin; score 1 denoted a mild
and patchy increase in the inflammatory cells; score 2
denoted a prominent inflammatory reaction forming a
continuous band at the invasive margin with some
evidence of destruction of cancer cell islands and score 3
denoted a florid ‘cup-like’ inflammatory infiltrate at the
invasive edge with frequent destruction of cancer cell
islands. All specimens (tumours with 5 mm of adjacent
non-cancerous tissues) were collected and embedded in
paraffin for immunohistochemical study.
Immunohistochemistry
All tissues were fixed in 10% neutral buffered formalin
and embedded in paraffin using standard surgical pa-
thology protocols. Tissue sections (4 μm) were dewaxed
and antigen retrieval was performed in citrate buffer
(pH = 6) for 5 min using a microwave oven. Immunohis-
tochemical staining procedures were performed in line
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antibodies were used in immunohistochemical studies:
iNOS (clone [M-19]-G, 1:100 dilution; Santa Cruz,
Heidelberg, Germany) and D2-40 antigen (clone D2-40;
1:50 dilution; Signet Laboratories, Dedham, MA, USA).
Immunohistochemical reactions were developed with
diaminobenzidine as the chromogenic peroxidase sub-
strate. The sections were counterstained with hematoxy-
lin after immunohistochemistry [6,8].
Specificity was verified by negative control reactions
without primary mAbs and by the appropriate reaction for
each antigen in positive control tissues. The immunohis-
tochemically stained sections were reviewed indepen-
dently by two pathologists (NK, NOK) without knowledge
of the patients’clinicopathological details. When disagree-
ment arose, the slides in question were jointly reviewed.
Assessment of immunohistochemical stain of iNOS
iNOS expression in pathology specimens was analyzed in
3 different localizations: tumor cells (iNOS-T), endothelial
cells (iNOS-E), and tumor-associated stromal fibroblasts
(iNOS-F). To score the iNOS staining pattern, only cells
with evidence of cytoplasmic, perinuclear and luminal
staining were considered positive [5,7,9-11,18-20]. The
intensity of immunostainings with iNOS antibodies was
evaluated by dividing the staining reaction into four
scores: 1 = weak, 2 =moderate, 3 = strong, and 4 = very
strong staining intensity. The quantity of the immuno-
staining was scored as follows; 0 = no positive immuno-
staining, 1 = <25%, 2 = 25–49%, 3 = 50–75%, and 4= >75%
of cells showing immuno-positivity. By adding up the
qualitative and quantitative scores, a sum score was
obtained, which was then divided into five main groups: -
(score 0) = no immunostaining; + (score 1–2) = weak
immunostaining; ++ (score 3–4) =moderate immuno-
staining; +++ (score 5–6) = strong immunostaining; ++++
(score 7–8) = very strong immunostaining [18-20].
Assessment of immunohistochemical stain of D2-40:
Lymphatic invasion (LI), lymphatic invasion density (LID
[nLI/mm2]), and lymphatic vascular density (LVD)
In order to determine LI, LID [nLI/mm2], and LVD,
LECs spesific D2-40 mAb was used. Non-neoplastic
tumor-adjacent lymphatic endothelial cells were used as
internal positive controls for D2-40. LI of the tumor was
established when at least one neoplastic cell cluster was
clearly visible inside a D2-40 positive lymph vessel,
following Yamauchi et al. [16]. Total LI number (nLI)
was determined for each case as whole slide being
treated with D2-40 immunohistochemically. Tissue areas
in sections D2-40 was applied were measured using
digital planimeter (Visitrak, Smith&- Nephew, 00 00 00
42 17) in each case as previously described [21]. LI num-
ber in a mm2 was determined via dividing nLI in eachcase by tissue area. Total tissue area measured in gastric
carcinoma cases is 9664 mm2 (mean ± SD; 235.71 ±
57.38, range 133–376).
The method of quantifying LVD has been reported
previously [19-21]. The D2-40 stained sections were first
scanned at low magnification (100×) to select ten “hot-
spots” (areas with the greatest amount of distinct brown
staining) in each tumor [22-24]. These hotspots were
then counted at 400× with a microscope ocular grid
corresponding to an examination area of 0.1885 mm2
(i.e., 40 × objective lens and 10× ocular lens; 0.1885 mm2
per field). Any immunostained cells or separate clusters of
endothelial cells, with or without an identifiable lumen,
were considered and counted as a single vessel. Depen-
ding on the size of the hot spot, 1 to 3 readings were
taken. In the absence of apparent hot spots, 10 randomly
selected areas were counted. The LVD for each case was
expressed by the mean value (total number of vessels in
10 hot spot microscopic fields/10). For each case, the
peritumoral LVD (P-LVD) [hot spots selected in the
peripheral tissues within 2 mm of the tumour margins]
and intratumoral LVD (I- LVD) [hot spots located within
the tumour and surrounded by tumor cells] were calcu-
lated separately [22-24].
Statistical analysis
Statistical analyses were performed with SPSS 18.0 soft-
ware (SPSS Inc., Chicago, IL, USA). Distribution of data
was determined by Shapiro-Wilks test. Continuous vari-
ables were expressed as mean ± std. deviation, catego-
rical variables as frequency and percent. Continuous
variables were compared with independent sample t test
or the Mann–Whitney U test for two group. The one
way analysis of variance (ANOVA) or Kruskal-Wallis
test was used to determine for differences between
three or more groups. The Tukey test was used as a
post hoc test, if the Anova test is statistically signifi-
cant. Bonferroni adjusted Mann–Whitney U test was
used for post-hoc test after Kruskal-Wallis test. Pearson’s
or Spearman’s correlation analysis was performed to de-
termine the relationship between continious variables. p
value of less than 0.05 was considered statistically signifi-
cant for all tests.
Results
Clinical and pathological findings




Gastric carcinoma cases Analysis of iNOS expression
in tumor cells revealed that five (12.2%) cases showed no
iNOS expression (Score 0). Thirty-six (87.8%) cases had
Table 1 Clinicopathologic characteristics of gastric
carcinoma cases
Clinicopathologic variables Number of cases (n) Percent
(%)
Age (years) 62.00 ± 10.94
(range: 35–82)




















Mucinous/poorly cohesive 10 24.4
Differentiation
Well/moderate 20 48.7
















Table 1 Clinicopathologic characteristics of gastric
carcinoma cases (Continued)
Inflammatory response
Score 0 0 0
Score 1 11 26.8
Score 2 12 29.3
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(mean ± standard deviation): 4.05 ± 2.46; range: 1–8].
iNOS immunoreactivity was heterogeneous among the
different types of tumors and/or in the same tumor.
Although weak/focal/luminal staining (score 1–2) was fre-
quently present at well-differentiated tumor sites, a strong/
homogeneous/cytoplasmic reaction (score 7–8) was evi-
dent at poorly differentiated tumor sites (Figure 1A-B).
None of the gastric carcinoma cases displayed iNOS
expression in the non-neoplastic epithelium (Figure 1C).
Seven (17.1%) cases had a strong iNOS immunoreaction in
invasive tumor cells that had lost their polarities and adhe-
sions [epithelial–mesenchymal transition (EMT)-like dedif-
ferentiation] (Figure 1D) [24]. In all the gastric carcinoma
samples, varying degrees of iNOS expression were detected
in endothelial cells (iNOS-E score: 5.88 ± 2.02; range 2–8)
(Figure 1E) and tumor-associated stromal fibroblasts
(iNOS-F score: 4.71 ± 1.61; range 2–8) (Figure 1F).
The iNOS scores of all cellular components of gastric
carcinoma cases are summarized in Table 2.
Non-neoplastic gastric tissue None of the non-
neoplastic gastric mucosa samples were positive for iNOS
expression in epithelial cells. Of these cases, 20% (n = 4)
exhibited focal/weak iNOS expression (score 1–2) in stro-
mal fibroblasts and the vascular endothelium. In all cases,
strong iNOS immunoreactivity (score 7–8) was detected
in macrophages and neutrophils, which were used as
internal positive controls [25-29]. No immunoreaction
was observed in negative controls performed without
using a primary antibody in any cellular component.
D2-40
Lymphatic invasion density (LID [nLI/mm2]) D2-40,
developed against the oncofetal membrane antigen M2A,
is a mAb with an immunoglobulin-G2a (IgG2a) structure
that is sensitive to lymphatic endothelial podoplanin.
Figure 1 iNOS immunoreactivity in gastric carcinoma tissue. (A) A focal/weak/luminal immunoreaction is observed in a well-differentiated
adenocarcinoma case. (B) Intense/diffuse/cytoplasmic iNOS immunoreactivity is observed in a poorly differentiated tumor tissue. (C) No iNOS
expression was detected in non-neoplastic glands in the same case. (D) Despite focal/weak iNOS immunoreactivity in well-differentiated tumor
areas, there is strong iNOS expression in tumor cells of the invasive phenotype. iNOS immunoreactivity is demonstrated in endothelial cells
(E) and fibroblasts (F) in the tumor stroma.
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lymphatic invasion (LI) in 35 (85.4%) cases (Figure 2A-B).
The presence of multiple sites of LI (n > 1) was observed
in 100% (n = 41) LI cases (14.39 ± 17.32; range, 1–52). The
LID [nLI/mm2] of all gastric carcinoma cases was 0.07 ±
0.15 (range, 0.00–0.88).
Intratumoral (I-LVD) and peritumoral lymphatic vas-
cular density (P-LVD) In all cases, lymphatic endothe-
lial cells and/or a lymphatic vascular structure was
detected in intratumoral and peritumoral areas that
reacted with D2-40. The lymphatic vessels in the
intratumoral area were few in number, had a narrow
lumen, and were collapsed. In the peritumoral area,however, lymphatic vessels were more prominent, thin
walled, irregular, and dilated (Figure 2C-F). The mean
P-LVD and I-LVD levels were 13.05 ± 5.67 (median 11.7;
range, 5.7–32) and 6.96 ± 3.98 (median 6.0; range, 1–24.3),
respectively.
The distribution of LI, LID [nLI/mm2], and P-LVD
and I-LVD levels by clinicopathological parameter is
shown in Table 3.
Non-neoplastic gastric mucosa In all non-neoplastic
gastric mucosa samples (n = 20; 100%), lymphatic vessels
were observed in immunohistochemical studies with
D2-40. The mean LVD level in non-neoplastic gastric
mucosa was 3.72 ± 1.15.
Table 2 Distribution of iNOS scores of tumor cells (iNOS-
T), tumor-associated stromal fibroblasts (iNOS-F), and
endothelial cells (iNOS-E) according to clinicopathologic
parameters in cases with gastric carcinoma
Variables iNOS Score [Mean ± SD (Min.-Max.)]
iNOS-T iNOS-F iNOS-E
Histological type
NOS/tubular/papillary 2.6 ± 2.3 (0–6) 4.8 ± 1.7 (2–8) 5.9 ± 2.1 (2–8)
Mucinous/poorly
cohesive
4.8 ± 2.2 (2–8) 4.4 ± 1.9 (2–7) 5.9 ± 2.7 (2–8)
Differentiation
Well/moderate 2.6 ± 2.3 (0–6) 4.6 ± 2.2 (0–8) 5.6 ± 2.8 (2–8)
Poorly/signet ring cell 4.8 ± 2.2 (2–8) 4.3 ± 1.3 (0–8) 6.0 ± 1.6 (2–8)
pN
N0 1.3 ± 1.8 (0–5) 2.9 ± 1.3 (2–5) 3.2 ± 1.9 (2–7)
N1 4.1 ± 1.3 (2–6) 5.9 ± 1.6 (4–8) 6.7 ± 1.7 (4–8)
N2 4.1 ± 1.9 (2–8) 4.9 ± 1.2 (3–7) 6.6 ± 1.3 (4–8)
N3 5.9 ± 2.2 (2–8) 5.2 ± 1.2 (3–7) 6.6 ± 1.1 (4–8)
pT
T1 1.5 ± 1.1 (0–7) 2.4 ± 1.2 (2–7) 3.1 ± 1.7 (2–7)
T2 4.2 ± 1.5 (2–6) 5.4 ± 1.7 (4–8) 6.8 ± 1.8 (4–8)
T3 4.4 ± 1.9 (2–8) 4.9 ± 1.5 (3–7) 6.2 ± 1.7 (4–8)
T4 5.9 ± 2.1 (2–8) 5.1 ± 1.4 (3–7) 6.9 ± 1.2 (4–8)
TNM stage
I 0.0 ± 0.0 (0–0) 3.3 ± 1.5 (2–5) 4.0 ± 2.6 (2–7)
II 3.2 ± 1.8 (0–6) 4.4 ± 1.9 (2–8) 5.0 ± 2.4 (2–8)
III 5.4 ± 3.2 (2–8) 5.3 ± 1.3 (3–7) 6.8 ± 1.0 (4–8)
IV - - -
Total 4.0 ± 2.5 (0–8) 4.0 ± 2.5 (0–8) 5.9 ± 2.0 (2–8)
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iNOS activity in tumor tissue specimens: correlation with
clinicopathological parameters and lymphangiogenesis
iNOS expression in tumor cells (iNOS-T) There was
a statistically significant positive correlation between
iNOS-T and LID [nLI/mm2], I-LVD, and P-LVD.
There was a significant difference between iNOS-T
and the local inflammatory response, LVI, LI, lymph node
involvement, and histological grade (all p-values < 0.05).
Tumors with an inflammation score of 3 had a higher
iNOS-T score compared with tumors with an inflam-
mation score of ½. Poorly differentiated/signet ring cell
carcinoma cases had higher iNOS-T scores than well-/
moderately differentiated carcinomas. iNOS-T scores of
the cases with negative lymph node status were sig-
nificantly lower than those with positive lymph node in-
volvement. iNOS-T scores of LVI- and LI-positive
cases were significantly higher than LVI and LI nega-
tive cases.iNOS expression in tumor-associated stromal fibro-
blasts (iNOS-F) There was a positive, weak correlation
between iNOS-F and LID [nLI/mm2], I-LVD, and iNOS-T.
A positive, strong correlation was evident between iNOS-F
and iNOS-E. There was a significant difference between
pN categories with respect to iNOS-F (pN0 or pN1/2/3).
The iNOS-F score in the PN0 category was significantly
lower than in other categories (all p-values < 0.05).
iNOS activity in endothelial cells (iNOS-E) There was
a positive, weak correlation between iNOS-E and the
number of metastatic lymph nodes, nLI, LID [nLI/mm2],
and P-LVD (all p-values < 0.05).
D2-40
LID (nLI/mm2) and LVD: correlation with clinicopathologic
parameters
LID (nLI/mm2) There was a positive correlation bet-
ween LID (nLI/mm2) and the number of metastatic
lymph nodes, I-LVD, P-LVD, and the density of inflam-
mation. There was a statistically significant difference
between the histologic grade categories regarding LID
(nLI/mm2). LID (nLI/mm2) was higher in cases with
poorly differentiated/signet ring cell carcinoma compa-
red with well-/moderately differentiated carcinomas
(all p-values < 0.05).
I-LVD and P-LVD A strong, positive correlation was
found between I-LVD and the number of metastatic
lymph nodes, tumor diameter, the density of inflam-
mation, and P-LVD. There was a significant difference
between histologic grade categories (well-/moderately
differentiated or poorly differentiated/signet ring cell)
with respect to I-LVD. I-LVD was noted to be signifi-
cantly higher in the poorly differentiated tumor group
(all p-values < 0.05).
There were significant positive correlations between
P-LVD and the number of metastatic lymph nodes,
tumor diameter, and density of inflammation. There was
a significant difference between histologic grade catego-
ries with respect to P-LVD. P-LVD was noted to be sig-
nificantly higher in the poorly differentiated tumor group
(all p-values < 0.05).
The mean LVD in the non-neoplastic gastric mucosa
was found to be lower than the mean I-LVD (p = 0.003)
and P-LVD (p < 0.001) levels of gastric carcinoma cases.
The results of all statistical analyses are shown in
Tables 4 and 5.
Discussion
The lymphatic system serves as the primary route for
metastatic spread of gastric carcinomas, and the pres-
ence and extent of lymph node involvement are the
principal parameters affecting survival [30-32]. Growth
Figure 2 D2-40 immunoreactivity in gastric carcinoma cases. (A-B) Tumor cell emboli are observed within lymphatic vessels in a case with
gastric carcinoma with diffuse lymphovascular invasion (A, H&E; B, D2-40). (C-D) Dilated lymphatic vessels are displayed in the peritumoral area in
a poorly differentiated adenocarcinoma case (C, H&E; D, D2-40). Intratumoral lymphatic vessels with a narrow lumen are demonstrated in a well
differentiated (E) and poorly differentiated (F) adenocarcinoma cases (E-F, D2-40).
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lymphangiogenesis increase in malignant melanoma and
breast, lung, and colon carcinoma [30-33]. Many studies
have suggested that lymphangiogenesis is a more reliable
parameter than angiogenesis in predicting tumor pro-
gression [30-34]. Despite all these data, how gastric
tumor cells reach the potential to metastasize via lym-
phatic vessels and the biological role of tumor-associated
lymphangiogenesis in the development of nodal metasta-
ses remain unclear.
Various methods are used to determine lymphangio-
genic activity. Some studies have supported that the rate of
LEC proliferation reflects lymphangiogenic activity [34,35].
In most studies, LVD detection using lymphatic vessel
endothelium-specific monoclonal antibodies (mAbs) is a
reliable indicator of lymphangiogenesis [30-39]. Therefore,we considered lymphatic endothelial cells to be inde-
pendent of their proliferative activity. Using lymphatic
endothelium-specific markers is a reliable method in the
determination of lymphatic vessels and real LI in tumor
tissue. For this purpose, many lymphatic endothelium-
specific mAbs (e.g., anti-VEGFR-3, anti-LYVE-1, anti-Prox-
1, anti-LyP-1, and anti-Nrp2) have been produced. D2-40
is the preferred mAb for investigating intratumoral and
peritumoral lymphatics because it is more convenient and
more sensitive than other lymphatic markers [40]. In our
study, we used podoplanin (clone D2-40) to determine LI
and LVD; its reliability has been proven in previous studies
[33-36,40].
The microvascular density (MVD) method used by
Weidner et al. for the determination of tumor angioge-
nesis is the most commonly used for LVD determination
Table 3 Distribution of lymphatic invasion density (LID [nLI/mm2]), peritumoral lymphatic vascular density (P-LVD),
and intratumoral lymphatic vascular density (I-LVD) according to clinicopathologic parameters in cases with gastric
carcinoma
Variables Mean ± SD (Min.-Max.)
LID P-LVD I-LVD
Histological type
NOS/tubular/papillary 0.06 ± 0.16 (0–0.8) 12.8 ± 2.7 (7.2–15.7) 6.9 ± 4.4 (1–24.3)
Mucinous/poorly cohesive 0.11 ± 0.13 (0–0.8) 13.8 ± 5.4 (5.9–21.6) 6.9 ± 2.6 (3.5–10)
Differentiation
Well/moderate 0.01 ± 0.01 (0–0.03) 10.2 ± 2.7 (7.2–15.7) 5.2 ± 2.1 (1–8.7)
Poorly/signet ring cell 0.10 ± 0.18 (0–0.88) 14.5 ± 6.2 (5.7–32) 6.9 ± 2.6 (3.5–10.2)
pN
N0 0.001 ± 0.003 (0–0.03) 8.1 ± 1.7 (5.9–11.7) 3.5 ± 1.5 (1–5.5)
N1 0.02 ± 0.01 (0–0.04) 8.6 ± 1.9 (5.7–11) 4.8 ± 1.9 (3–8.7)
N2 0.03 ± 0.03 (0–0.02) 12..6 ± 2.5 (9–17.5) 6.8 ± 1.9 (3.5–9.3)
N3 0.18 ± 0.2(0–0.9) 19.1 ± 5.3 (13.7–32) 10.6 ± 4.4 (6–24.3)
pT 0.001 ± 0.003 (0–0.03) 8.1 ± 1.7 (5.9–11.7) 3.5 ± 1.5 (1–5.5)
T1 0.0 ± 0.0 (0–0) 7.9 ± 1.1 (7.2–8.7) 3.9 ± 0.6 (3.4–4.3)
T2 0.0 ± 0.01 (0–0.01) 10.8 ± 7.2 (5.7–16) 6.4 ± 3.2 (4.1–8.7)
T3 0.04 ± 0.05 (0–0.27) 11.8 ± 4.1 (5.9–22.1) 5.9 ± 2.8 (1–11.3)
T4 0.16 ± 0.3 (0–0.88) 19.1 ± 5.3 (13.7–32) 9.6 ± 5.2 (4.3–24.3)
TNM stage
I 0.0 ± 0.0 (0–0) 7.7 ± 0.9 (7.2–8.7) 2.9 ± 1.7 (1–4.3)
II 0.01 ± 0.02 (0.0–0.05) 9.5 ± 2.9 (5.7–16) 4.6 ± 1.9 (1.1–8.7)
III 0.13 ± 0.2 (0.01–0.88) 16.2 ± 5.6 (9–32) 9 ± 4.2 (7.9–11.5)
IV - - -
Total 0.07 ± 0.15 (0–0.88) 13.1 ± 5.7 (5.7–32) 6.9 ± 3.9 (1–24.3)
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in three areas where vascular structures are most dense
(hot spot) is sufficient to determine tumor angiogenesis
[23]. However, tumor-associated lymphatic vessels are
fewer and more dispersed than blood vessels. Thus,
assessment of an area as large as possible for the deter-
mination of LVD will be a more reliable marker of
lymphangiogenic activity [24,26,35]. Thus, the mean
number of lymphatic vessels in 10 hot spots was used as
the LVD in this study.
In our study, varying numbers of lymphatic endothe-
lium/vessels were present in both intratumoral and
peritumoral areas in all cases with gastric carcinoma.
Lymphatic vessels in intratumoral areas were of imma-
ture appearance and collapsed. Lymphatic vessels were
concentrated in peritumoral areas. Peritumoral lymph-
atic vessels had thin walls, irregular shapes, and dilated
appearances. It has been argued that compression by
tumor cells and oncotic pressure increase in intratu-
moral areas, causing lymphatic vessels to be few in num-
ber and have a narrow lumen [41]. The morphological
findings of our study support this view. In agreementwith previous studies, we found that P-LVD was signifi-
cantly higher than I-LVD. A positive correlation was
found between I-LVD and P-LVD [26,42-46]. This finding
suggests that lymphangiogenic growth factors expressed
from the tumor microenvironment affect intratumoral
and peritumoral areas to different extents; however, the
lymphangiogenic activity at both localizations is closely
interrelated.
Lymphatic vessels are highly dynamic structures that
intimately interact with their surrounding microenviron-
ment. They have a profound influence on the immune
system and therefore can manipulate inflammatory
processes. Inflammation is a major cause of adulthood
lymphangiogenesis and lymphovascular remodeling [41].
Our study demonstrated that lymphatic vessel density in
tumor tissue (I-LVD and P-LVD) was positively corre-
lated with the extent of the local inflammatory response.
Our findings suggest that the immune response to the
tumor is a lymphangiogenesis-inducing factor and may
play a role in the formation of tumor lymphatic metasta-
ses. Cytokines and the metabolic load increase during
inflammation may cause this phenomenon [41].
Table 4 Results of statistical analyses between
immunohistochemical and clinicopathologic parameters
in cases with gastric carcinoma
Variables iNOS score D2-40
iNOS-T iNOS-S iNOS-E LID P-LVD I-LVD
Age*
r value 0.007 0.008 0.07 0.06 0.05 0.01
p Value 0.92 0.96 0.86 0.71 0.99 0.85
Gender (male or female)**
p Value 0.67 0.93 0.34 0.84 0.20 0.15
Location of tumor (proximal or distal) **
p Value 0.53 0.17 0.005 0.95 0.77 0.60
Tumor size (cm)*
r value 0.31 0.06 0.06 0.29 0.53 0.37
p Value 0.05 0.70 0.70 0.07 < 0.001 0.01
Histological type (NOS/tubular/papillary or mucinous/poorly cohesive)
**
p Value 0.46 0.54 0.51 0.14 0.44 0.62
Differentiation (Well/moderate or poorly/signet ring cell) **
p Value 0.01 0.748 0.92 0.001 0.001 0.03
Inflammatory response (score 1 + 2 or score 3) **
p value 0.01 0.89 0.51 0.02 0.001 0.01
LVI [H&E](positive or negative) **
p Value 0.002 0.03 0.01 0.001 0.001 < 0.001
LI [D2-40](positive or negative) **
p Value 0.002 0.02 0.01 < 0.001 0.001 < 0.001
nLI*
r value 0.64 0.37 0.44 0.98 0.65 0.63
p Value < 0.001 0.017 0.004 < 0.001 < 0.001 < 0.001
nNm*
r value 0.61 0.30 0.40 0.83 0.86 0.78
p Value < 0.001 0.05 0.009 < 0.001 < 0.001 < 0.001
pN (N0 or N1/2/3) **
p Value 0.001 0.003 0.023 < 0.001 < 0.001 < 0.001
pT (T1 + 2 orT3 + 4) **
p Value 0.05 0.70 0.70 0.07 < 0.001 0.01
TNM stage (I + II or III + IV) **
p Value 0.0002 0.067 0.02 < 0.001 < 0.001 < 0.001
* Pearson’s correlation analysis/Spearman’s correlation analysis and
**Independent sample t test/the Mann–Whitney U tests were used.
Table 5 Results of statistical analyses* of the relationship
of iNOS scores at different cellular localizations and
lymphatic invasion density (LID [nLI/mm2]), peritumoral
lymphatic vascular density (P-LVD), and intratumoral
lymphatic vascular density (I-LVD)
Variables iNOS-T iNOS-F iNOS-E LID P-LVD I-LVD
LID
r value 0.64 0.39 0.45 - 0.65 0.63
p value 0.001 0.013 0.004 - 0.001 0.001
P-LVD
r value 0.56 0.27 0.35 0.65 - 0.84
p value 0.001 0.08 0.02 0.001 - 0.001
I-LVD
r value 0.59 0.32 0.25 0.63 0.84 -
p value 0.001 0.04 0.11 0.001 0.001 -
* Pearson’s correlation analysis/Spearman’s correlation analysis were used.
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prognosis and short survival in breast, colon, and lung
cancers [26,31,44,45]. However, the effect of I-LVD on
tumor progression remains a controversial issue [26-34].
Our study demonstrated that both I-LVD and P-LVD
were positively correlated with LI, LID, the presence of
lymph node metastasis, and the number of metastatic
lymph nodes. Those findings show that an increase inlymphangiogenic activity accelerates the development of
nodal metastases by facilitating the transport of tumor
cells to lymphatic vessels. Furthermore, our findings
suggest that both I-LVD and P-LVD can be used for the
prediction of lymphatic spread of the tumor.
The genesis of lymph node metastasis in tumors is a
complex and multifactorial process. Invasion of lym-
phatic vessels at the primary tumor focus by tumor cells
is the first and primary step. However, LI cannot be
regarded as the sole indicator of lymph node metastasis
because of the antitumor defense mechanisms of the
host and tumor-associated lymphatic vessels containing
anatomically/functionally abnormal features. An increa-
sed LI number in tumor tissue will increase the likeli-
hood of metastasis by causing more tumor cells to enter
the circulation [16,25,26,38,39]. Therefore, we assessed
tumor cell entry into the lymphatic circulation using two
parameters: nLI and LID (nLI/mm2). We detected a
significant positive relationship between nLI, and LID
and the presence of lymph node metastasis, and the
number of metastatic lymph nodes. Our results suggest
that the presence of multiple lymphatic invasion sites at
the primary tumor focus increases the chance of tumor
cells metastasizing to lymph nodes. In addition, LID may
be a more reliable marker for predicting lymph node
metastasis than LVI or LI.
It has been demonstrated in vitro and in vivo that NO
molecules exert significant effects on tumor lymphangio-
genesis and lymphatic spread in addition to tumor
angiogenesis. NO induces the proliferation of lymphatic
endothelial cells and prolongs their survival by increa-
sing lymphangiogenic growth factors (e.g., VEGF-C/
VEGF-D) and VEGFR-2/VEGFR-3 expression in tumor-
associated lymphatic vessels [8]. It has been determined
that the increase in NOS activity in tumor tissue is
positively correlated with lymphatic metastasis in head
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http://www.diagnosticpathology.org/content/8/1/151and neck, breast, thyroid, and gall bladder cancers and
malignant melanomas [3-8]. Lahdenranta et al. reported
that blocking NOS activity in fibrosarcomas prevented
peritumoral lymphatic hyperplasia and tumor cell spread
to lymph nodes [6].
Studies of iNOS expression in gastric carcinomas
frequently indicate a relationship between NO and angio-
genesis. Few studies have examined the relationship bet-
ween NOS and lymphangiogenesis in gastric carcinomas.
Wang et al. determined that, compared with normal
gastric tissue, gastric carcinomas exhibited greater iNOS
expression. In that study, it was determined that iNOS
expression in tumor cells is a reliable marker of the iNOS
mRNA level [11]. Koh et al. reported that iNOS expres-
sion was closely related to the loss of differentiation in
tumor cells and elevated levels of pro-inflammatory cyto-
kines (e.g., TNFα) [19]. Li et al. identified moderate-to-
high iNOS expression in 62% of gastric carcinomas. These
researchers found a significant correlation between iNOS
expression in tumor cells and tumor size, invasion depth,
lymph node involvement, and TNM stage [18]. Zhang
et al. reported that iNOS expression was an independently
associated with survival [5].
We did not identify iNOS expression in non-neoplastic
gastric epithelial cells. We found varying degrees of iNOS
expression in tumor cells in 87.8% of gastric carcinoma
cases. We also identified a significant correlation between
iNOS expression in tumor cells and inflammation density,
loss of differentiation, and parameters related to lymphatic
tumor spread/lymphangiogenesis. We found that iNOS
expression was more prominent, particularly in EMT-like
dedifferentiation areas with loss of cohesion and an inva-
sive phenotype. Our results suggest that tumor cells are a
principal source of iNOS, and an increase in iNOS activity
has the potential to modulate lymphangiogenic activity in
gastric carcinomas. Furthermore, our results indicate that
tumor cells with a less differentiated/invasive pheno-
type express more iNOS, and that this increased iNOS
expression contributes to metastatic spread. Similar to
Koh et al. [19], we showed that iNOS expression and
the inflammatory response had a positive correlation.
Our findings suggest that the increase in iNOS expres-
sion in tumor cells is a common factor that induces
both a tumor-associated inflammatory response and
lymphangiogenesis.
iNOS is expressed primarily by macrophages and neu-
trophils [2-8,29]. In neoplastic tissues, tumor cells are a
primary source of iNOS. Thomsen et al. showed that
stromal fibroblasts and endothelial cells expressed iNOS,
and stromal iNOS expression was correlated with tumor
grade in breast carcinomas [29]. We assessed iNOS
expression in various cellular components of gastric
carcinomas separately, and found that iNOS expression
in tumor cells and iNOS expression in stromal cells werepositively correlated. Our findings indicate that the NO
level in the microenvironment of the tumor may be
elevated by iNOS originating from various cellular compo-
nents. In addition, we also found that iNOS expression in
the tumor stroma was related to tumor lymphangiogenesis
and lymphatic spread. However, compared with that
originating from tumor cells, iNOS expression from
tumor-associated stroma appears to play a less important
biological role.Conclusions
In conclusion, we found that both intratumoral and
peritumoral LVD were closely related to lymph node
metastasis, the most important parameter of the bio-
logical behavior of a tumor, in gastric carcinomas. We
also found that iNOS may be expressed by different
cellular components in tumor tissues; indeed, iNOS
expressed by tumor cells may play an important role in
the pathogenesis and progression of gastric carcinomas.
Our finding of an increase in the iNOS level in EMT-
like dedifferentiation areas, reflecting transformation of
tumor cells into an invasive and a metastatic phenotype,
supports this result. In addition, our findings indicate
the potential of an iNOS-mediated NO increase to
modulate lymphangiogenesis and lymphatic spread in
gastric carcinomas. Therefore, development of novel
agents that inhibit iNOS activity and NO signal conduc-
tion may represent an alternative treatment of gastric
carcinomas.Consent
Written informed consent was obtained from the patient
for the publication of this report and any accompanying
images.
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